Chris Shibutani: I have 2 questions, There was recent just some initial preclinical data for their compound. They screened against . Can you provide us with any thoughts on whether you think this was an appropriate comparator for them to screen against? And potentially, what differences this might have with respect to 6291, just put some perspective on benchmarking.
Mark Goldsmith: Yes. I guess, first, in terms of the data that we’ve seen publicly it seems as if their comparator was really KRAS G12C(OFF) inhibitors. And we would expect to see a difference in KRAS G12C(OFF) inhibitors. We published, as you know, extensively on in in vivo models, a large number of in vivo lung cancer models versus a G12C(OFF) inhibitor. I think they showed 1 or 2 models. So it’s really hard to comment on how active that compound is. We’re comparing a very large data set with a very small data set. I don’t know what to do with that. I think in terms of conceptually, it’s not clear to us why having G12C(OFF) inhibitory activity is advantageous if you have a G12C(ON) inhibitor. In other words, the on form is the active pool.
It’s the oncogenic protein and the (OFF) protein is not active. So it’s not clear to us and frankly, an experiments in which we combined RMC-6291 with a KRAS G12C (OFF) inhibitor, we didn’t see any advantage over RMC6291. So conceptually, we’re not sure why there would be in the advantage. And from a data point of view, it’s just comparing apples and oranges at this point. So we just keep moving 691 forward.
Chris Shibutani: And then using 018, would no reference anything to compare there with 691.
Mark Goldsmith: M&A, that was a tool compound that Brian Cortland reported and it’s not an in vivo tool compound. So I’m not really sure I’m not sure why we would compare to a tool compound. RMC-6291 is the development candidate that’s now being dosed in humans I don’t think that they use — I think they used R018 because it was available. Yes. I don’t think it’s a relevant comparator.
Chris Shibutani: Got it. And then finally, you’re going to be announcing a fifth less on candidate. I think we’ll get that disclosure before the end of the year. Any hands as to the potential venue for that?
Mark Goldsmith: Yes, I don’t know if it will be disclosed just before the end of the year or just after the end of the year. But we will select it by the end of the year and there may not really be much of a venue to do that. But once we get into the early part of 2023, there are some investor venues that might be available to us.
Operator: Our next question comes from Jay Olson with Oppenheimer.
Jay Olson: We’re curious to know your views on the collaboration that was announced today between Incyte and Mirati to combine insights oral small molecule PD-L1 inhibitor with Mirati’s adagrasib. Any comments you could share with us? Would you go par to your thoughts about the deal and any plans you may have for partnering your RAS(ON) inhibitors with molecules in development at other companies in terms of types of combinations that would be synergistic and whether or not you think it’s important to have an all-oral combination regimen versus combining your oral drugs with an antibody would be great?
